Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Intratracheal Administration of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in a Patient with Acute Respiratory Distress Syndrome

  • Chang, Youjin (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan) ;
  • Park, So Hee (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan) ;
  • Huh, Jin-Won (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan) ;
  • Lim, Chae-Man (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan) ;
  • Koh, Younsuck (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan) ;
  • Hong, Sang-Bum (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan)
  • Received : 2013.03.10
  • Accepted : 2013.09.01
  • Published : 2014.03.10
⟨ Previous Next ⟩

Abstract

Umbilical cord blood (UCB)-derived mesenchymal stem cells (MSCs) have been introduced as a possible therapy in acute lung injury and acute respiratory distress syndrome (ARDS). This case history is reported of a 59-yr-old man who was treated with MSCs in the course of ARDS and subsequent pulmonary fibrosis. He received a long period of mechanical ventilation and weaning proved difficult. On hospital day 114, he underwent the intratracheal administration of UCB-derived MSCs at a dose of $1{\times}10^6/kg$. After cell infusion, an immediate improvement was shown in his mental status, his lung compliance (from $22.7mL/cmH_2O$ to $27.9mL/cmH_2O$), $PaO_2/FiO_2$ ratio (from 191 mmHg to 334 mmHg) and his chest radiography over the course of three days. Even though he finally died of repeated pulmonary infection, our current findings suggest the possibility of using MSCs therapy in an ARDS patient. It is the first clinical case of UCB-derived MSCs therapy ever reported.

Keywords

References

  1. Loebinger MR, Janes SM. Stem cells for lung disease. Chest 2007; 132: 279-85. https://doi.org/10.1378/chest.06-2751
  2. Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011; 29: 913-9. https://doi.org/10.1002/stem.643
  3. Matthay MA, Goolaerts A, Howard JP, Lee JW. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med 2010; 38(10 Suppl): S569-73. https://doi.org/10.1097/CCM.0b013e3181f1ff1d
  4. Mac Sweeney R, McAuley DF. Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial? Thorax 2012; 67: 475-6. https://doi.org/10.1136/thoraxjnl-2011-201309
  5. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86. https://doi.org/10.1016/S0140-6736(08)60690-X

Cited by

  1. Severe infections in neutropenic patients vol.21, pp.6, 2015, https://doi.org/10.1097/mcc.0000000000000256
  2. Epithelial Sodium Channels in Pulmonary Epithelial Progenitor and Stem Cells vol.12, pp.9, 2014, https://doi.org/10.7150/ijbs.15747
  3. Sepsis and Acute Respiratory Distress Syndrome: Recent Update vol.79, pp.2, 2014, https://doi.org/10.4046/trd.2016.79.2.53
  4. Prospects and progress in cell therapy for acute respiratory distress syndrome vol.16, pp.11, 2014, https://doi.org/10.1080/14712598.2016.1218845
  5. Stem/progenitor cells in endogenous repairing responses: new toolbox for the treatment of acute lung injury vol.14, pp.None, 2016, https://doi.org/10.1186/s12967-016-0804-1
  6. Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis vol.8, pp.18, 2014, https://doi.org/10.18632/oncotarget.15426
  7. Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study vol.2018, pp.None, 2014, https://doi.org/10.1155/2018/5268057
  8. Mesenchymal stem cells: A double‐edged sword in radiation‐induced lung injury vol.9, pp.2, 2014, https://doi.org/10.1111/1759-7714.12573
  9. Risk factors and prognosis of acute respiratory distress syndrome following abdominal surgery vol.17, pp.1, 2019, https://doi.org/10.3892/etm.2018.6928
  10. The rationale of using mesenchymal stem cells in patients with COVID‐19 ‐related acute respiratory distress syndrome: What to expect vol.9, pp.11, 2020, https://doi.org/10.1002/sctm.20-0164
  11. Cell‐based therapy to reduce mortality from COVID ‐19: Systematic review and meta‐analysis of human studies on acute respiratory distress syndrome vol.9, pp.9, 2014, https://doi.org/10.1002/sctm.20-0146
  12. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome vol.12, pp.10, 2014, https://doi.org/10.4252/wjsc.v12.i10.1067
  13. Stem cell-based therapy for COVID-19 and ARDS: a systematic review vol.6, pp.1, 2014, https://doi.org/10.1038/s41536-021-00181-9
  14. Mesenchymal stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies vol.12, pp.1, 2014, https://doi.org/10.1186/s13287-021-02496-2